The Food and Drug Administration approved the first single medication to treat hepatitis C on Friday, green-lighting one pill in the place of multiple treatments. The new drug, Harvoni, is the third hepatitis C drug approved in the past year.

“With the development and approval of new treatments for hepatitis C virus, we are changing the treatment paradigm for Americans living with the disease,” said FDA official Edward Cox.

Harvoni, developed by Gilead Sciences, will be the first hepatitis drug to require a pill only once daily. A full 12-week treatment will cost $94,500, less than existing treatments, Reuters reports.

Write to Justin Worland at justin.worland@time.com.